<DOC>
	<DOCNO>NCT00029107</DOCNO>
	<brief_summary>The purpose study assess efficacy Rituximab ( anti-CD20 ) treatment patient hepatitis C associate cryoglobulinemic vasculitis ( HCV-CV ) fail intolerant interferon-alpha/ribavirin therapy . Up 75 patient may screen enroll 34 adult patient active HCV-CV randomized , non-blinded phase I/II trial . Patients randomize receive either Rituximab 375 mg/M ( 2 ) day 1 , 8 , 15 22 beginning time enrollment standard therapy . Patients group maintain stable dos immunosuppressive therapy receive time enrollment . Response Rituximab assess clinical laboratory parameter . Although cause cryoglobulinemic vasculitis know , critical component presence cryoglobulins-abnormal protein white blood cell call B lymphocyte produce response chronic hepatitis C infection . Rituximab decrease number B cell . The Food Drug Administration approve Rituximab 1997 treatment B-cell non-Hodgkin 's lymphoma . Patients 18 75 year age hepatitis C sign symptom cryoglobulinemic vasculitis may eligible study . They must fail , unable tolerate , treatment IFN-a ribavirin . Candidates screen history physical examination , electrocardiogram ( ECG ) , blood urine test , 24-hour urine collection chest X-ray , clinically indicate . Participants randomly assign receive Rituximab upon enter study 6 month enter study . Those whose treatment delay 6 month follow month NIH disease evaluation blood test time . Patients give Rituximab intravenously ( vein ) week 4 week . For first dose , patient admit hospital least 24 hour infusion monitoring . Subsequent infusion give inpatient outpatient basis , depend infusion tolerate . The day infusion history physical examination , blood work , test , X-rays , clinically indicate . After four infusion , patient follow drug side effect response treatment . They blood test every week 4 week return NIH 1 day every month 12 month physical examination , blood test , X-rays , medically indicate . Visits may frequent , necessary , patient may ask stay longer day test finding requ ...</brief_summary>
	<brief_title>Rituximab Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis</brief_title>
	<detailed_description>Although cause cryoglobulinemic vasculitis know , critical component presence cryoglobulins-abnormal protein white blood cell call B lymphocyte produce response chronic hepatitis C infection . Rituximab decrease number B cell . The Food Drug Administration approve Rituximab 1997 treatment B-cell non-Hodgkin 's lymphoma . Patients 18 75 year age hepatitis C sign symptom cryoglobulinemic vasculitis may eligible study . They must fail , unable tolerate , treatment IFN-a ribavirin . Candidates screen history physical examination , electrocardiogram ( ECG ) , blood urine test , 24-hour urine collection chest X-ray , clinically indicate . Participants randomly assign receive Rituximab standard therapy 6 month enter study . All patient follow month NIH disease evaluation blood test time . Patients give Rituximab 375 mg/m2intravenously week 4 week . The day infusion history physical examination , blood work , test , X-rays , clinically indicate . After four infusion , patient follow drug side effect response treatment . They blood test every week 4 week return NIH 1 day every month 12 month physical examination , blood test , X-rays , medically indicate . Visits may frequent , necessary .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Cryoglobulinemia</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>INCLUSION CRITERIA : Diagnosis HCVCV : must follow HCV infection document serology and/or plasma HCV RNA . One organ system objective evidence active vasculitis : Palpable purpura ; Glomerulonephritis ( define presence glomerular hematuria and/or new worsen proteinuria ) ; Acute peripheral neuropathy . Detectable cryoglobulins and/or RF . Failure treatment IFNalpha ribavirin control manifestation HCVCV OR intolerance IFNalpha/ribavirin regimen . Patients must personal physician responsible care HCV . Ages 18 75 year Willingness use effective contraception 12 month follow Rituximab treatment . Effective contraception method include abstinence , surgical sterilization either partner , barrier method diaphragm , condom , cap sponge , hormonal contraception . EXCLUSION CRITERIA : Recent ( within 4 week ) initiation increase immunosuppressive therapy . Active systemic infection ( hepatitis C ) . Pregnancy breast feeding . Prior treatment Rituximab . Known allergy murine protein . Significant renal insufficiency ( creatinine clearance le 30 ml/min ) . Presence lifethreatening HCVCV ; define rapidly progressive glomerulonephritis ( define double serum creatinine 3 month period ) , CNS vasculitis , cardiac disease due active vasculitis , GI vasculitis ( defined ischemic bowel , perforation , infarction ) . Significant hepatic insufficiency manifest ChildPugh classification B C. History variceal bleeding , encephalopathy . History liver transplantation . Coinfection either HBV HIV . Any underlying medical condition judgment investigator would put patient increase risk serious infusionrelated adverse event .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Hepatitis</keyword>
	<keyword>Vasculitis</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Cryoglobulinemia</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>HcV-cV</keyword>
	<keyword>Cryoglobulinemic Vasculitis</keyword>
</DOC>